Zai Lab Limited
NASDAQ:ZLABBiotechnology
+$0.61 today
- Market cap
- $2.49B
- Beta
- 0.78
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.16
Volume 1.04M
Average 0.87M
ZLAB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Zai Lab LimitedNASDAQ: ZLAB
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$46.09M, compared with -$35.73M a year earlier. Trailing-twelve-month EBITDA was -$168.8M.
Context
- EBITDA amounted to 34.4% of revenue in FY2025, down 26.5 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$191.18M (-20.8%) for the fiscal year ending Dec 2026, a slowdown from the +34.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$46.09M-4.8% QoQ
- Last fiscal yearDec 2025
- -$158.25M+34.9% YoY
- LTMJun 2026
- -$168.8M+13.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -29.0% | -97.1% | -68.1 pp |
| 1 year | +34.9% | -20.8% | -55.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (158.25M) USD
- Year-over-year change
- +34.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (158.25M) | +34.9% |
| FY2024 | 2024-12-31 | (242.99M) | +33.4% |
| FY2023 | 2023-12-31 | (365.11M) | +16.0% |
| FY2022 | 2022-12-31 | (434.84M) | +36.9% |
| FY2021 | 2021-12-31 | (689.46M) | — |
EBITDA vs competitors
How ZLAB compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +13.6% is the 2nd highest of 3, against a peer median of -133.8%.
- EBITDA amounts to 37.5% of revenue for ZLAB, versus a peer median of 196.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2025 | -$7.49M USD | +93.2% | — | 1.2% | |
| LTM Jun 2024 | -$63.57M USD | — | — | 979.5% | |
| LTM Jun 2026 | -$168.8M USD | +13.6% | — | 37.5% | |
AAPGAscentage Pharma Group International | FY2025 | -CN¥1.1B CNY | -360.8% | — | 196.1% |
| Peer median (excluding ZLAB) | — | -133.8% | — | 196.1% | |
Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 144.31M | 215.04M | 266.72M | 398.99M | 460.16M |
| Cost of Revenue | 52.24M | 74.02M | 95.82M | 147.86M | 191.08M |
| Gross Profit | 92.07M | 141.02M | 170.9M | 251.13M | 269.08M |
| Gross Margin | 63.8% | 65.6% | 64.1% | 62.9% | 58.5% |
| Research & Development | 573.31M | 286.41M | 265.87M | 234.5M | 220.9M |
| Selling, General & Admin | 218.83M | 258.97M | 281.61M | 298.74M | 277.61M |
| Operating Expenses | 792.14M | 545.38M | 537.48M | 533.25M | 492.65M |
| Depreciation & Amortization | 6.49M | 8.23M | 9.03M | 11.86M | 15.01M |
| EBITDA | (689.46M) | (434.84M) | (365.11M) | (242.99M) | (158.25M) |
| EBITDA Margin | -477.8% | -202.2% | -136.9% | -60.9% | -34.4% |
| Operating Income | (700.06M) | (404.36M) | (366.57M) | (282.12M) | (223.57M) |
| Operating Margin | -485.1% | -188.0% | -137.4% | -70.7% | -48.6% |
| Interest Income | 2.19M | 14.58M | 39.8M | 37.11M | 33.05M |
| Interest Expense | 0 | 0 | 0 | 2.25M | 5.21M |
| Other Income / Expenses | (3.35M) | (38.93M) | 31.95M | 25.01M | 45.11M |
| Income Before Tax | (703.41M) | (443.29M) | (334.62M) | (257.1M) | (178.46M) |
| Pre-Tax Margin | -487.4% | -206.1% | -125.5% | -64.4% | -38.8% |
| Income Tax Expense | 1.06M | 0 | 0 | 0 | (2.93M) |
| Net Income | (704.47M) | (443.29M) | (334.62M) | (257.1M) | (175.54M) |
| Net Margin | -488.2% | -206.1% | -125.5% | -64.4% | -38.1% |
| EPS (Basic) | (75.80) | (46.30) | (34.60) | (2.60) | (1.60) |
| EPS (Diluted) | (75.80) | (46.30) | (34.60) | (2.60) | (1.60) |
| Weighted Avg Shares | 9.3M | 9.58M | 9.66M | 98.95M | 109.53M |
| Weighted Avg Shares (Diluted) | 9.3M | 9.58M | 9.66M | 98.95M | 109.53M |
Zai Lab Limited
NASDAQ:ZLAB
Intrinsic Alpha fair value
Locked
Current Price
$22.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.